entrepreneurship@UBC Lab2Launch Venture Building Program

July 7, 2020
entrepreneurship@UBC

Lab2Launch entrepreneurship@UBC’s Lab2Launch venture building program is for UBC researchers and scientists who are focusing on the development of a scientific or technological innovation which is unique, proprietary and difficult to reproduce, propelling them through venture creation, team building, investment and growth.  Formerly known as the Life Science Incubator program About entrepreneurship@UBC entrepreneurship@UBC propels UBC innovations out … Continue reading entrepreneurship@UBC Lab2Launch Venture Building Program

Genome British Columbia Annual Report for the fiscal year 2019/2020, celebrating our 20th anniversary.

Genome British Columbia

On behalf of the Board of Directors and staff, I am pleased to share with you a copy of the Genome British Columbia Annual Report for the fiscal year 2019/2020, celebrating our 20th anniversary. Twenty years ago, the budding genomics revolution offered enormous potential for the future and Genome BC’s goal was to be a catalyst … Continue reading Genome British Columbia Annual Report for the fiscal year 2019/2020, celebrating our 20th anniversary.

InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755

InMed Pharmaceuticals Inc.

Vancouver, BC – July 7, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), today announced that dosing of subjects has begun in its second Phase 1 clinical trial with INM-755 (“755-102-HV”). … Continue reading InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755

Canadian Firm Plays Key Role in COVID-19 Vaccine Development Project with BioNTech and Pfizer

July 3, 2020
Acuitas Therapeutics

July 1, 2020 – Vancouver, B.C. – Acuitas Therapeutics, a Vancouver-based biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP), is seeing its already substantial reputation as a global expert in this area go further. This is because the company is playing a key role … Continue reading Canadian Firm Plays Key Role in COVID-19 Vaccine Development Project with BioNTech and Pfizer

Neoleukin Therapeutics Announces Pricing of $76.2 Million Public Offering

July 2, 2020
Neoleukin Therapeutics, Inc.

SEATTLE, July 02, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the pricing of an underwritten public offering of 3,262,471 shares of its common stock at a price to the public of $15.25 per share. In addition, and in lieu of common stock, Neoleukin is offering … Continue reading Neoleukin Therapeutics Announces Pricing of $76.2 Million Public Offering

Neoleukin Therapeutics Announces Proposed Public Offering

Neoleukin Therapeutics, Inc.

SEATTLE, July 01, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, up to 5.0 million shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded … Continue reading Neoleukin Therapeutics Announces Proposed Public Offering

InMed Announces Completion of Share Consolidation

June 30, 2020
InMed Pharmaceuticals Inc.

Trading of Consolidated Shares on TSX Expected to Begin on July 3rd, 2020 Vancouver, BC – June 30, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), is pleased … Continue reading InMed Announces Completion of Share Consolidation

adMare BioInnovations Launches a New Acceleration Program for Quebec Emerging Companies

adMare BioInnovations

New program supported by the Quebec Government and the City of Montreal looks to scale-up the province’s most promising young life sciences companies. Montreal, QC – June 29th, 2020: adMare BioInnovations (adMare) is pleased to announce the creation of the adMare Accelerate Program for Quebec emerging companies. The Program is designed to advance a key … Continue reading adMare BioInnovations Launches a New Acceleration Program for Quebec Emerging Companies

Kardium receives CE mark for Globe® Mapping and Ablation System Announces launch of commercial sales in Europe

Kardium Inc.

June 30, 2020 9:00 AM Pacific Standard Time VANCOUVER, British Columbia – Kardium Inc. has received CE mark approval for its Globe Mapping and Ablation System – the most complete solution for the treatment of atrial fibrillation (AF). AF is the world’s most common heart rhythm disorder, affecting more than 37 million people. This approval … Continue reading Kardium receives CE mark for Globe® Mapping and Ablation System Announces launch of commercial sales in Europe

MSFHR Funds COVID-19 Research To Mitigate Effects On BC’s Vulnerable Populations

Michael Smith Foundation for Health Research

Mitigating the impact of COVID-19 on newcomers to BC, urban Indigenous people, frontline health-care workers, and those in prisons or precarious housing is the focus of many of the funded researchers from the MSFHR COVID-19 Research Response Fund, announced today. Other research teams will investigate testing the body’s response to COVID-19, detecting future waves of … Continue reading MSFHR Funds COVID-19 Research To Mitigate Effects On BC’s Vulnerable Populations